A031704 || PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]

Learn more:
http://www.clinicaltrials.gov/ct2/show/NCT03793166

Protocol Number

C-403

Phase

III

Management Group

Oncology Network

Oncology Group

GU Oncology Group

Disease Sites

Bones and Joints
Kidney
Sarcoma
Urinary Bladder

Sponsor Protocol

PDIGREE
A031704

Principal Investigator

Louis Crain Garrot

Scope

National

Participating Institutions

Atlanta Cancer Care - Atlanta
Atlanta Cancer Care - Cumming
Atlanta Cancer Care - Stockbridge
Georgia Cancer Specialists - Athens
Georgia Cancer Specialists - Blairsville
Georgia Cancer Specialists - Canton
Georgia Cancer Specialists - Cumming
Georgia Cancer Specialists - Decatur
Georgia Cancer Specialists - Macon
Georgia Cancer Specialists - Marietta
Georgia Cancer Specialists - Northside
Suburban Hematology Oncology Associates - Duluth
Suburban Hematology Oncology Associates - Lawrenceville
Suburban Hematology Oncology Associates - Snellville

Find Open Clinical Trials

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]

Want to learn more?